| Name | Title | Contact Details |
|---|
The Kentucky Association of Health Care Facilities/Kentucky Center for Assisted Living (KAHCF/KCAL) is the trade association that represents propriety and non-proprietary nursing facilities, personal care homes, and assisted living communities across the Commonwealth. One of the state affiliates of the American Health Care Association/National Center for Assisted Living (AHCA/NCAL), KAHCF/KCAL provides a wide variety of services to member facilities including legislative and regulatory activities, professional development, statewide recognition programs, publications, media relations, research and advocacy relations.
Expresso fitness headquartered in Santa Clara, CA is the industry leader in gamified fitness for the commercial market. Over the past 15 years, Expresso has brought millions of riders adventure, challenges and community on their world class interactive connected bikes. The company is on a mission to bring people together through fitness with innovative, social, and immersive workouts. With over 100 million workouts where members ride in virtual worlds, push themselves with heart rate training, and HIIT workouts inspired by gaming, the company is well on its way to make that happen.
Supplements made to the highest standards, and formulated to make a real difference in your life. Find your next game changer from the supplement brand you can trust.
The Brain Tumor Society is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.